EUVIMEDEUVIMED entdecken
Editorial

Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer

Vaibhav Sahai, Al B Benson

NEJM Evidence · 2024

DOI: 10.1056/evide2300341 ↗

Kurz gefasst

Editorial in der Zeitschrift NEJM Evidence, 2024. Verfasst von Vaibhav Sahai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabinePancreatic NeoplasmsHumansAlbuminsAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidinePaclitaxelRandomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Substanzen

AlbuminsDeoxycytidineGemcitabinePaclitaxel

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.
  • Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago.

Zitieren

APA

Sahai, V., & Benson, A. B. (2024). Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer. NEJM Evidence. https://doi.org/10.1056/evide2300341

Vancouver

Sahai V, Benson AB. Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer. NEJM Evidence. 2024. doi:10.1056/evide2300341

BibTeX
@article{Sahai2024,
  author = {Sahai, Vaibhav and Benson, Al B},
  title = {Are We There Yet? — Alternating Chemotherapy Regimens in Pancreatic Cancer},
  journal = {NEJM Evidence},
  year = {2024},
  doi = {10.1056/evide2300341}
}
Kostenlos starten →